Who are Avacta?
Our mission is to shape the future of medicine by developing safe and efficacious drugs based on our proprietary Affimer® platform and by providing powerful Affimer® reagents for research and diagnostics.
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.
Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
“What really excites me, and drives the company, is the opportunity to change the way life scientists explore the complexity of the proteome and the myriad of interactions that define us as humans.”
Alastair Smith, CEO Avacta.